AIM CONCEPT INTEGRATION
3rd Year MBBS
Foundation Module
3rd Year MBBS
Foundation Module
Pharmacodynamics, Drug Receptors and Dose–Response Relationships
Connect drug targets, receptor signaling, dose–response behavior, therapeutic safety and antagonism into one rapid-revision pharmacodynamic framework.
“`
1. THE TOPIC IN ONE CONNECTED FLOW
Pharmacodynamics connects a drug’s interaction with its biological target to the response produced in cells, tissues and patients. Receptor activation or blockade changes intracellular signaling, which determines the magnitude of effect. Dose–response curves then help compare potency, efficacy and antagonism, while therapeutic indices describe the separation between benefit and toxicity.
STAGE 1
Drug reaches a target
Receptor, enzyme, ion channel or transporter
→
STAGE 2
Target activity changes
Agonism, partial agonism, antagonism or inverse agonism
→
STAGE 3
Signal transduction
cAMP, IP3, DAG, Ca2+ or cGMP pathways
→
STAGE 4
Cellular response
Altered contraction, secretion, metabolism or excitability
→
STAGE 5
Dose–response relationship
Potency, efficacy and population response become measurable
→
STAGE 6
Therapeutic safety
ED50, TD50, therapeutic index and therapeutic window
2. KEY CLINICAL CONNECTIONS
Receptor Adaptation
Prolonged receptor stimulation
→
down-regulation or desensitization
→
reduced response to the same drug.
→
down-regulation or desensitization
→
reduced response to the same drug.
Prolonged receptor blockade
→
up-regulation
→
exaggerated response when blockade is removed.
→
up-regulation
→
exaggerated response when blockade is removed.
Dose–Response Interpretation
Leftward curve position
→
lower dose needed
→
greater potency.
→
lower dose needed
→
greater potency.
Higher maximal response
→
greater Emax
→
greater efficacy.
→
greater Emax
→
greater efficacy.
Antagonism on the Curve
Reversible competitive blockade
→
rightward shift
→
Emax preserved.
→
rightward shift
→
Emax preserved.
Non-competitive blockade
→
reduced functional response capacity
→
Emax falls.
→
reduced functional response capacity
→
Emax falls.
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Drug binding → receptor activation → intracellular signaling → cellular response: this is the central pharmacodynamic sequence.
Full agonist → maximal receptor activation; partial agonist → lower efficacy; antagonist → affinity without activation; inverse agonist → reduces constitutive activity.
Serpentine receptor → G-protein signaling → second messengers; cAMP, IP3, DAG, Ca2+ and cGMP transmit and amplify receptor signals.
⭐ Spare receptors → maximal effect before complete receptor occupancy; receptor reserve explains why loss of some receptors may initially leave Emax unchanged.
Graded response → magnitude in an individual system; quantal response → proportion of a population achieving a defined therapeutic or toxic endpoint.
⭐ Potency → dose required; efficacy → maximum achievable effect. A less potent drug may still be clinically preferable if it has greater efficacy.
Therapeutic index = TD50/ED50; protective index uses TD1/ED99 and provides a more stringent comparison of therapeutic safety.
⭐ AIM Exam Trap: A reversible competitive antagonist reduces apparent agonist potency and shifts the curve right while preserving Emax; non-competitive antagonism reduces Emax because increasing agonist concentration cannot fully restore the response.